Through this long-term strategic partnership agreement, the Institut Pasteur and AlterDiag will carry out research and development projects to develop new single-domain antibodies (VHH) -based rapid diagnostic tests using lateral flow immunochromatography, with the aim of strengthening the fight against infectious diseases.
Scientific and technological collaboration to meet global health challenges
By combining the cutting-edge expertise of Dr. Rose and his team, in charge of the Institut Pasteur's diagnostic test development and innovation platform, in the characterization and integration of VHH in immunoassays with AlterDiag's expertise in the development, regulatory registrations and commercialization of rapid diagnostic tests.
As part of the collaboration, the team intends to use single-domain antibodies (VHH) associated with immunochromatography methods to detect pathogens not currently addressed by rapid tests performed close to the patient, or to substantially improve the performance of existing tests. These innovations will meet the expectations of healthcare professionals, and are in line with WHO recommendations for more accessible rapid diagnostics.
Research supported by state-of-the-art infrastructures
A strong collaboration between researchers from the Institut Pasteur and AlterDiag will carry out part of the research and development of these new tests at the Diagnostic Test Innovation and Development Core Facility under the direction of Dr. Thierry Rose. This platform set up by the Institut Pasteur, co- funded by BPI from 2021 is supported by the Région Ile de France by a SESAME Filières Program.
AlterDiag will then take full responsibility for the industrialization, regulatory registrations and commercialization of these tests.
After co-development of prototype tests using VHH on the platform, AlterDiag will then take full responsibility for the key stages of industrialization, regulatory registration and marketing of the tests developed.
Unique potential to revolutionize infectious disease diagnostics
“We are very excited to bring our innovations in immunoassays to point-of-care by joining forces with the company AlterDiag to meet the WHO's commitments in protecting health for all. An initial list of five pathogens responsible for diseases targeted by the WHO has been drawn up, and the first research projects are about to start”, said Dr. Rose, Head of Diagnostic Test Innovation and Development Core Facility at the Institut Pasteur.
About Diagnostic Test Innovation and Development Core Facility at the Institut Pasteur, Paris:
The core facility’s ambition is to develop serological or antigenic in vitro diagnostic test (IVD) as fast as possible, since 2020 for SARS-CoV-2, today for other viral, microbial or parasitic infectious agents, and tomorrow for global health applications on human, animal and environmental samples. The cross- disciplinary talents of our team weave together physics, chemistry, biology and engineering to imagine and design the diagnostic health tests of the future.
For more information, please visit
